Ghanizadeh Ahmad, Tordjman Sylvie, Jaafari Nematollah
Research Center for Psychiatry & Behavioral Sciences; Department of Psychiatry; Substance Abuse Research Center; Department of Neuroscience, School of Advanced Medical Sciences & Technologies, Shiraz University of Medical Sciences, Shiraz, France.
Indian J Med Res. 2015 Sep;142(3):269-75. doi: 10.4103/0971-5916.166584.
BACKGROUND & OBJECTIVES: No clear therapeutic benefits of antipsychotics have been reported for the treatment of behavioural symptoms in autism. This systematic review provides an assessment of evidence for treating irritability in autism by aripiprazole.
The databases of MEDLINE/PubMed and Google Scholar were searched for relevant articles about the effect of aripiprazole in children with autism. The articles were searched according to the inclusion and exclusion criteria specifed for this review. All the double-blind, controlled, randomized, clinical trials examining the efficacy of aripiprazole for treating children and adolescents with autism were included.
From the 93 titles identified, 26 were irrelevant and 58 were evaluated for more details. Only five articles met the inclusive criteria. The evidence from precise randomized double blind clinical trials of aripiprazole for the treatment of autism in children and adolescents was convincing enough to recommend aripiprazole. Adverse effects were not very common and were usually mild.
INTERPRETATION & CONCLUSIONS: Current evidence suggests that aripiprazole is as effective and safe as risperidone for treating irritability in autism. However, further studies with larger sample size and longer duration are required.
尚无关于抗精神病药物治疗孤独症行为症状有明确治疗益处的报道。本系统评价旨在评估阿立哌唑治疗孤独症易激惹症状的证据。
检索MEDLINE/PubMed和谷歌学术数据库中关于阿立哌唑对孤独症儿童影响的相关文章。根据本评价指定的纳入和排除标准进行检索。纳入所有检验阿立哌唑治疗孤独症儿童和青少年疗效的双盲、对照、随机临床试验。
从识别出的93篇标题中，26篇不相关，58篇进行了更详细的评估。只有5篇文章符合纳入标准。阿立哌唑用于治疗儿童和青少年孤独症的精确随机双盲临床试验证据足以推荐使用阿立哌唑。不良反应并不常见，且通常较轻微。
目前证据表明，阿立哌唑在治疗孤独症易激惹症状方面与利培酮一样有效且安全。然而，需要进一步开展更大样本量、更长疗程的研究。
